Yeekian Chuenrutai, Geratikornsupak Nopavut, Chumpongthong Pongsak, Tongsiri Sirinat, Dhitavat Jittima, Phonrat Benjaluck, Pitisuttithum Punnee
J Med Assoc Thai. 2014 Apr;97(4):447-55.
To study and to compare the medical and economic burden among chronic hepatitis B (CHB) patients.
A prospective observational study was conducted among 129 adult CHB patients. The medical burden was assessed by using the EuroQol-5D (EQ-5D) and the Chronic Liver Disease Questionnaire (CLDQ) at initial day, the six and 12-month follow-up. The economic burden was assessed in term of total cost per case per year
At one-year follow-up, the mean age of 129 patients was 41.6 (SD = 11.8) years. For medical burden at over time, CHB with antiviral drugs (ARV) for hepatitis B infection had a significant decreased in percentage of anxiety, and increased the mean (SD) CLDQ score. The mean total costs per case per year of CHB without ARV (52 cases), CHB with antiviral drugs (50 cases), and CHB with cirrhosis/hepatocellular carcinoma (HCC) with ARV (27 cases) were significantly different (p < 0.001) with USD 615.9 (SD = 688.0), 1,777.4 (SD = 1,220.4), and 2,651.3 (SD = 3,885.0), respectively.
CHB causes a great economic burden in Thailand Early antiviral drugs treatment prevents complication in CHB patients.
研究并比较慢性乙型肝炎（CHB）患者的医疗和经济负担。
对129例成年CHB患者进行前瞻性观察研究。在初始日、随访6个月和12个月时，使用欧洲五维健康量表（EQ-5D）和慢性肝病问卷（CLDQ）评估医疗负担。从每年每例患者的总成本方面评估经济负担。
在一年的随访中，129例患者的平均年龄为41.6（标准差=11.8）岁。随着时间推移，对于医疗负担，使用抗乙肝病毒药物（ARV）的CHB患者焦虑百分比显著降低，且慢性肝病问卷（CLDQ）平均（标准差）得分升高。未使用ARV的CHB患者（52例）、使用ARV的CHB患者（50例）以及伴有肝硬化/肝细胞癌（HCC）且使用ARV的CHB患者（27例）每年每例患者的平均总成本有显著差异（p<0.001），分别为615.9美元（标准差=688.0）、1777.4美元（标准差=1220.4）和2651.3美元（标准差=3885.0）。
CHB在泰国造成巨大经济负担。早期使用抗病毒药物治疗可预防CHB患者出现并发症。
